Delcath Systems to Present at Upcoming Virtual Investor Conferences
September 02 2021 - 9:00AM
Delcath Systems, Inc. (Nasdaq:
DCTH), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, announced today it will
participate in three upcoming conferences:
H.C. Wainwright 23rd Annual Global Investment
Conference: September 13th to 15th, 2021
- Presentation Date
and Time: On-demand beginning 9/13/2021 at 7:00 AM (ET)
-
Webcast: https://journey.ct.events/view/ee8971f7-2bcf-428c-91e5-3ff7d70376ab
- Management will
also host 1x1 investor meetings during the conference.
Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit: September 20-23
- Presentation Date
and Time: 9/21/2021 12:25 PM (ET)
-
Webcast: https://wsw.com/webcast/oppenheimer16/dcth/2754601
- Management will
also host 1x1 investor meetings during the conference.
Cantor Fitzgerald Healthcare Conference: September 27th
to 30th, 2021
- Presentation Date
and Time: 9/29/2021 4:40 PM (ET)
-
Webcast: https://wsw.com/webcast/cantor12/dcth/2065630
- Management will
also host 1x1 investor meetings during the conference.
To learn more or to schedule a one-on-one meeting with
management, please contact your conference representative or
james@haydenir.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, and is considered a
combination drug and device product regulated by the United States
Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver. CHEMOSAT is being marketed under an exclusive
licensing agreement with medac GmbH, a privately held
multi-national pharmaceutical company headquartered in Germany that
specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara (646)-755-7412 james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Oct 2023 to Oct 2024